Robert “Bert” Hazlett

Contact Us
Robert (Bert) Hazlett is a Managing Director and Biotechnology Equity Research Analyst at BTIG. He provides coverage of companies in several therapeutic categories in the biotechnology sector, with a focus on CNS, oncology and anti-infective companies. Prior to BTIG, Mr. Hazlett was a Biotechnology Equity Research Analyst at Ladenburg Thalmann & Co., and a Senior Research Analyst at Roth Capital Partners. Previously, he accumulated over a decade of experience as a Senior Analyst covering both the large capitalization and emerging pharmaceuticals sectors while at BMO Capital Markets, SunTrust Robinson Humphrey, Lehman Brothers and UBS. Mr. Hazlett also served as a consultant for several emerging biotechnology companies throughout his career. In 2015, he was named a top stock picker in the biotechnology sector by Thomson Reuters’ StarMine Analyst Awards. Mr. Hazlett began his career as a Portfolio Manager in the Money Markets Division at the U.S. Trust Company of New York. He earned a BA from Yale University, and an MBA from Columbia University.

Coverage Area

Company Ticker
Akebia Therapeutics, Inc. AKBA
ASLAN Pharmaceuticals Limited ASLN
Axsome Therapeutics, Inc. AXSM
Eiger BioPharmaceuticals, Inc. EIGR
Homology Medicines, Inc. FIXX
Intra-Cellular Therapies, Inc. ITCI
MannKind Corporation MNKD
Matinas BioPharma Holdings, Inc. MTNB
Nektar Therapeutics NKTR
Prothena Corporation PLC PRTA
Paratek Pharmaceuticals, Inc. PRTK
Syndax Pharmaceuticals, Inc. SNDX
TRACON Pharmaceuticals, Inc. TCON
Verastem, Inc. VSTM
Galera Therapeutics, Inc. GRTX
NextCure, Inc. NXTC
Lyra Therapeutics, Inc. LYRA
Aravive, Inc. ARAV
Seelos Therapeutics, Inc. SEEL
CTI Biopharma Corp. CTIC
COMPASS Pathways plc CMPS
Rani Therapeutics Holdings, Inc. RANI
Aura Biosciences, Inc. AURA